Acetazolamide Market, by Formulation (Tablets, Capsules and Injection), by Application (Glaucoma, Epilepsy, Drug-induced Edema, Altitude Sickness, Fluid Retention, Heart Failure and Seizures), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

  • Published On : Dec 2018 |
  • Pages : 152 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Acetazolamide Market – Global Industry Insights

Acetazolamide is carbonic anhydrase inhibitor, used in adjuvant treatment of chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma, epilepsy, edema due to congestive heart failure, drug-induced edema, and acute mountain sickness in climbers. Acetazolamide promotes acclimatization to altitude, increases bicarbonate secretion by the kidneys, induces metabolic acidosis, and stimulates ventilation. Furthermore, according to the BMJ Journal, September 2012, acetazolamide in doses of 250 mg, 500 mg, and 750 mg daily are more effective compared to placebo for preventing acute mountain sickness. In addition, acetazolamide 250 mg daily is the lowest effective dose to prevent acute mountain sickness.

The global acetazolamide market size was valued at US$ 183.2 Mn in 2017, and is expected to witness a CAGR of 4.8% during the forecast period (2018 – 2026).


Global Acetazolamide Market Share, By Formulation: 2018 & 2026

Source: Coherent Market Insights Analysis (2018)

Extended Application of Acetazolamide in Various Treatment Modalities is expected to Drive Market Growth during the Forecast Period

Acetazolamide is used to prevent high altitude illness in most people, which is characterized by headache, nausea, vomiting, and tiredness (often called acute mountain sickness), but may affect the brain or the lungs in different individuals. As per the study published in Cochrane Journal, in June 2017, acetazolamide is an effective and better treatment for the prevention of acute high altitude illness (HAI) in dosages of 250 to 750 mg/day, when compared to a placebo. Acetazolamide prevents acute mountain sickness and has fewer side effects than alternative drugs such as dexamethasone. According to BMJ journal, May 2018, prescribing acetazolamide for travel is an optional service and not included in the general practitioner’s contract in the U.K.

Researchers at the University of Chicago investigated acetazolamide, and published in the journal Science Translational Medicine, July 2018, stating that, altitude sickness drug, acetazolamide, helps to overcome resistance to chemotherapy drug temozolomide (TMZ). TMZ is frequently used in the treatment of gliomas, but some patients do not respond to the treatment. With the addition of acetazolamide, researchers identified an improvement in survival rates, in pre-clinical models of glioma. According to this study, acetazolamide when taken with TMZ, resulted in 30 to 40 percent increase in survival in animal models. Application of acetazolamide could be used as an alternative treatment solution for reducing resistance to chemotherapy in the treatment of gliomas, which offer lucrative growth opportunities for the drug in the market in the near future.

Furthermore, along with chronic simple (open-angle) glaucoma, secondary glaucoma and acute mountain sickness in climbers; acetazolamide is also indicated for adjective treatment of edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies.


Global Acetazolamide Market Share, By Application: 2018 & 2026

Source: Coherent Market Insights Analysis (2018)

Increasing Prevalence of Glaucoma among Global Population is expected to Aid in Market Growth  

Increasing prevalence of glaucoma and associated risk factors such as high myopia, diabetes, eye surgery or injury, high blood pressure, increased usage of corticosteroids, and family history of glaucoma among the global population are expected to offer conducive future growth for acetazolamide drug manufacturers. As a sustained release capsule of Acetazolamide taken a day, offers a substantial pressure-lowering effect that lasts at least 23 hours. Treatment with acetazolamide helps to reduce eye pressure, which aids in preventing eye damage. Acetazolamide works by blocking the action of an enzyme called carbonic anhydrase thereby, reducing the amount of fluid secreted in the front part of eye, thus lowering eye pressure. For instance, according to the study published in the Journal of Ophthalmology (2014), an estimated 64.3 million people (aged 40-80 years) in 2013, were affected with glaucoma, which would increase to 76.0 million in 2020, and 111.8 million in 2040.

According to the International Agency for the Prevention of Blindness, 2017, glaucoma is the second leading cause of blindness and leading cause of irreversible blindness worldwide. With primary angle closure glaucoma (PACG) being the most common in South-East Asia  while primary open-angle glaucoma (POAG) is mostly found among white Caucasians and individuals of Africa.

Among region, Asia Pacific is expected to be conducive region for the acetazolamide market growth. This is mainly owing to growing healthcare infrastructures, high prevalence of glaucoma, and associated risk factors such as diabetes and high blood pressure cases among the population of the region. For instance, according to American Academy of Ophthalmology (AAO), November 2013, glaucoma is the most common cause of preventable, irreversible blindness worldwide, among which primary open-angle glaucoma (POAG) is responsible for 12.3% of blindness. Furthermore, according to same source, POAG’s prevalence is estimated to be the highest among the people of China, intermediate in Japan, and lower in Europe and India. Therefore, these driving factors are expected to propel growth of acetazolamide market in Asia Pacific.

Key players operating in the acetazolamide market include Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Heritage Pharmaceuticals Inc., Nostrum Laboratories Inc., Novast Laboratories Ltd., Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.), Lannett Company, Inc., Strides Shasun Limited, and X-GEN Pharmaceuticals, Inc.

Acetazolamide is an enzyme inhibitor, which acts specifically on carbonic anhydrase. Acetazolamide, sold under the trade name Diamox, is used to treat glaucoma, altitude sickness, epilepsy, fluid retention, heart failure, and seizures.

In addition to this, acetazolamide (carbonic anhydrase inhibitor) is effective in controlling fluid secretions, to treat certain convulsive disorders, and promotes diuresis in instances of abnormal fluid retention such as cardiac edema.

Increasing effectiveness of acetazolamide in treating other indication such as drug induced edema and brain tumor glioblastoma is offering growth prospective for key drug manufacturers in this market. For instance, according to a new study published in Science Translational Medicine Journal in July 2018, acetazolamide may also be effective in treating glioblastoma, fast-growing brain tumor. As per the study findings, acetazolamide can restore temozolomide’s (TMZ) ability to kill tumor cells. Furthermore, the study suggested that the combination of acetazolamide with TMZ may be an effective subgroup to consider for trial for patients with high BCL-3 expression.

Market Dynamics

Increasing prevalence of glaucoma and its risk factors among global population is propelling demand for acetazolamide during the forecast period. Moreover, acetazolamide is commonly used for preventing high altitude illness, this increases the utility of the drug. 

For instance, according to the International Journal of Advanced Medical and Health Research, 2015, glaucoma is seen to be the second major reason causing blindness among people across the world, followed by cataract.

Furthermore, according to the BrightFocus Foundation, June 2017 data findings, over 3 million Americans suffer from glaucoma, out of which 2.7 million (aged 40 and older) are affected by its most common form, open-angle glaucoma. Also, high prevalence of eye disorder in the geriatric population and nutritional deficiency in the younger population due to changing food habits are other factors affecting the health of the people globally, which might lead to boost growth of acetazolamide market. Acetazolamide capsule taken once a day by patients with chronic glaucoma offers a substantial pressure-lowering effect, which lasts at least 23 hours.

Acetazolamide helps in preventing acute mountain sickness and has fewer side effects than alternative drugs such as dexamethasone, which can mask symptoms and therefore carries greater risk.  

Key features of the study:

  • This report provides in-depth analysis of acetazolamide market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, drug approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global acetazolamide market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as part of this study include Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Heritage Pharmaceuticals Inc., Nostrum Laboratories Inc., Novast Laboratories Ltd., Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.), Lannett Company, Inc., Strides Shasun Limited, and X-GEN Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future drug launch, manufacturing up-gradation, market expansion, and marketing tactics
  • The global acetazolamide market report caters to various stakeholders in this industry including investors, suppliers, acetazolamide based product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the acetazolamide market.

Detailed Segmentation:

  • Global Acetazolamide Market, By Formulation:
    • Tablets
    • Capsules
    • Injection
  • Global Acetazolamide Market, By Application:
    • Glaucoma
    • Epilepsy
    • Drug-induced Edema 
    • Altitude Sickness
    • Fluid Retention
    • Heart Failure
    • Seizures  
  • Global Acetazolamide Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Acetazolamide Market, By Geography:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Formulation:
        • Tablets
        • Capsules
        • Injection
      • By Application
        • Glaucoma
        • Epilepsy
        • Drug-induced Edema
        • Altitude Sickness
        • Fluid Retention
        • Heart Failure
        • Seizures
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Europe
      • By Country:
        • Germany
        • France
        • Italy
        • UK
        • Spain
        • Russia
        • Rest of Europe
      • By Formulation:
        • Tablets
        • Capsules
        • Injection
      • By Application
        • Glaucoma
        • Epilepsy
        • Drug-induced Edema
        • Altitude Sickness
        • Fluid Retention
        • Heart Failure
        • Seizures
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • South Korea
        • Australia
        • Rest of Asia Pacific
      • By Formulation:
        • Tablets
        • Capsules
        • Injection
      • By Application
        • Glaucoma
        • Epilepsy
        • Drug-induced Edema
        • Altitude Sickness
        • Fluid Retention
        • Heart Failure
        • Seizures
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Formulation:
        • Tablets
        • Capsules
        • Injection
      • By Application
        • Glaucoma
        • Epilepsy
        • Drug-induced Edema
        • Altitude Sickness
        • Fluid Retention
        • Heart Failure
        • Seizures
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Latin America
      • By Country:
        • Brazil
        • Argentina
        • Mexico
        • Rest of Latin America
      • By Formulation:
        • Tablets
        • Capsules
        • Injection
      • By Application
        • Glaucoma
        • Epilepsy
        • Drug-induced Edema
        • Altitude Sickness
        • Fluid Retention
        • Heart Failure
        • Seizures
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Africa
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
      • By Formulation:
        • Tablets
        • Capsules
        • Injection
      • By Application
        • Glaucoma
        • Epilepsy
        • Drug-induced Edema
        • Altitude Sickness
        • Fluid Retention
        • Heart Failure
        • Seizures
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments
      • Strategies
    • Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
    • Heritage Pharmaceuticals Inc.
    • Nostrum Laboratories Inc.
    • Novast Laboratories Ltd.
    • Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.)
    • Lannett Company, Inc.
    • Strides Shasun Limited
    • X-GEN Pharmaceuticals, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Formulation
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Epidemiology
    • Key Developments
    • Drug Approvals and Launches
    • Strategic Collaborations & Acquisitions
    • Regulatory Scenario
    • Pipeline Analysis
  4. Global Acetazolamide Market, By Formulation, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Tablets
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Capsules
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Injection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  5. Global Acetazolamide Market, By Application, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Glaucoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Epilepsy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Drug indicted Edema 
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Altitude Sickness
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Fluid Retention
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Heart Failure
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Seizures
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  6. Global Acetazolamide Market, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Online Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  7. Global Acetazolamide Market, By Region, 2018 - 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • North America
      • Market Size and Forecast, By Formulation, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Formulation, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Formulation, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Formulation, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Formulation, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Formulation, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Heritage Pharmaceuticals Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Nostrum Laboratories Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Novast Laboratories Ltd.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.)
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Lannett Company, Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • Strides Shasun Limited
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
      • X-GEN Pharmaceuticals, Inc.
        • Company Overview
        • Drug Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Key Strategies
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 23 market data tables and 25 figures on "Acetazolamide Market - Global forecast to 2026”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.